Lets start out by admitting this chart is horrendous viewing.
Arguments for entry are a mix of TA and FA
Retraced to a baseline support Volume on decline has been very low - relatively - disgruntled short termers have given up RSI is now oversold BB's are tightening
Results for year long trial with tier 1 partner due in next few weeks CAR T plyers starting to see some M&A action FDA are perceived to be leaning towards allowing therapies that may not have reached Phase III , if all else has failed
I am adding down here. They are going to need cash for trials but I suspect that comes from partners interested in their unique platform technologies. i think the next 8 weeks are going to see some healthy returns for the comp, but I think longer term tis is a good point to accumulate a few more
AUD$50m mkt cap is a joke - that's about US$33m and what most US biotech investors would call a steal.
